Distribution of phosphodiesterase type 5 (PDE5) in the lateral wall of the guinea pig urinary bladderDistribution of phosphodiesterase type 5 (PDE5) in the lateral wall of the guinea pig urinary bladder
Koeveringe, van, Gommert A.
Kerrebroeck, van, Philip E.V.
Faculty of Medicine and Health Sciences
Translational Neurosciences (TNW)
BJU international / British Association of Urological Surgeons. - Oxford, 1999, currens
112(2013):2, p. 246-257
Objective To study PDE5 localisation by visualising the product of phosphodiesterase type 5 (PDE5) inhibition, namely cGMP, to determine the site of action of inhibitors in the urinary bladder. Materials and Methods Bladders of nine male guinea pigs were dissected and treated in wells containing 2 mL Krebs' solution and 1 μM of the specific PDE5 inhibitor vardenafil at 36 °C for 30 min. After stimulating tissues with 100 μM of the nitric oxide (NO) donor diethylamine-NONOate for 10 min, the tissues were snap-frozen and 910 μm sections were cut. Sections were examined for cGMP immunoreactivity and also stained for vimentin, a marker for interstitial cells and the neuromarkers protein gene product 9.5 (PGP9.5), synaptic vesicle protein 2 (SV2), neurofilament (NF) and calcitonin gene-related peptide (CGRP), using the two-step indirect immunohistochemistry technique. Results After PDE5 inhibition, cGMP was found to be present in the urothelium, suburothelial interstitial cells and endothelium of blood vessels. cGMP was not expressed in nerves positive for CGRP, NF and SV2, and was expressed only in very few efferent nerves positive for PGP9.5. Conclusion Our data show that the possible sites of action of PDE5 inhibition in the bladder are the urothelium, suburothelial interstitial cells and blood vessels, rather than the bladder nerve fibres.